Table 4 Characteristics of CLL patients who died of COVID-19 (n = 56).
Characteristic | Result |
|---|---|
Median age, years (range, years) | 75.5 (51–91) |
Male/female | 38/18 |
Diagnosis | |
CLL (%) | 54 (96.4) |
SLL (%) | 1 (1.8) |
MBL (%) | 1 (1.8) |
Patients with comorbidities at the time of COVID-19 (%) | 46 (82.1) |
Median number of comorbidities (range) | 2 (1–9) |
Type of comorbidities | |
Hypertension (%) | 26 (46.4) |
Diabetes mellitus (%) | 10 (17.9) |
COPD (%) | 4 (7.1) |
Cardiovascular (%) | 10 (17.9) |
Respiratory (%) | 6 (10.7) |
Other malignancies (%) | 4 (7.1) |
CLL treatment history | |
Previously untreated (%) | 18 (32) |
Received treatment (%) | 38 (68) |
1 line of treatment | 21 |
2 lines of treatment | 8 |
3 lines of treatment | 5 |
4 lines of treatment | 3 |
>4 lines of treatment | 1 |
On treatment at the time of COVID-19 (%) | 19 (34) |
BTK inhibitor (acalabrutinib, ibrutinib) | 12 |
Venetoclax-based regimens | 1 |
Idelalisib | 1 |
Chemoimmunotherapy | 3 |
Corticosteroids | 1 |
Other (chemotherapy ± steroids) | 1 |
Hypogammaglobulinemia | |
Present (%) | 32 (64) |
Absent (%) | 18 (36) |
Missing information | 6 |
Pharmacological treatment for COVID-19 | |
Antivirals (%) | 30 (54) |
Hydroxychloroquine or similar (%) | 38 (68) |
Azithromycin (%) | 18 (32) |
Monoclonal antibodies against IL6/IL6R (%) | 9 (16) |
Management | |
Confinement at home | 1 (1.8) |
Hospitalization without need of oxygen | 0 |
Hospitalization with need of oxygen | 39 (69.6) |
Intensive care | 16 (28.6) |
